• Mutation; HGNC; HGNC:3236; EGFR; Simple; p.Ala763_Tyr764insPheGlnGluAla (c.2284-5_2290dup); ClinVar=VCV000045248; Zygosity=Unspecified (PubMed=24353160).
  

PubMed=24353160; DOI=10.1126/scitranslmed.3007205; PMCID=PMC3954775
Hiroyuki Yasuda, Eunyoung Park, Cai-Hong Yun, Natasha J. Sng, Antonio Roberto Lucena-Araujo, Wee-Lee Yeo, Mark S. Huberman, David W. Cohen, Sohei Nakayama, Kota Ishioka, Norihiro Yamaguchi ...Show all 24 authors... , Megan Hanna, Geoffrey Raymond Oxnard, Christopher S. Lathan, Teresa Moran, Lecia VanDam Sequist, Jamie E. Chaft, Gregory J. Riely, Maria E. Arcila, Ross A. Soo, Matthew Langer Meyerson, Michael J. Eck, Susumu S. Kobayashi, Daniel Botelho Costa; Show fewer authors
Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.
Sci. Transl. Med. 5:216ra177.1-216ra177.10(2013)

PubMed=31467113; DOI=10.1158/1541-7786.MCR-19-0419; PMCID=PMC6872223
Hibiki Udagawa, Shinichi Hasako, Akihiro Ohashi, Rumi Fujioka, Yumi Hakozaki, Mikiko Shibuya, Naomi Abe, Toshiharu Komori, Tomonori Haruma, Miki Terasaka, Ryoto Fujita ...Show all 18 authors... , Akihiro Hashimoto, Kaoru Funabashi, Hiroyuki Yasuda, Kazutaka Miyadera, Koichi Goto, Daniel Botelho Costa, Susumu S. Kobayashi; Show fewer authors
TAS6417/CLN-081 is a pan-mutation-selective EGFR tyrosine kinase inhibitor with a broad spectrum of preclinical activity against clinically relevant EGFR mutations.
Mol. Cancer Res. 17:2233-2243(2019)